GRAIL Inc (GRAL) Stock Price & Analysis
GRAL Stock Chart & Stats
- Day’s Range
- MXN 1,601.00 - MXN 2,800.00
- 52-Week Range
- MXN 825.00 - MXN 2,900.00
- Previous Close
- MXN 1,601.00
- Volume
- 0
- Average Volume (3M)
- 13
- Market Cap
- MXN 120.39B
- Enterprise Value
- MXN 2.17B
- Total Cash (Recent Filing)
- MXN 861.61M
- Total Debt (Recent Filing)
- MXN 91.31M
- Price to Earnings (P/E)
- ―
- Beta
- 2.71
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- -45.86
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Volume Growth
Strong growth in both test volume and revenue indicates expanding customer adoption and commercial reach. If sustained, higher throughput can improve operating leverage, support broader provider engagement, and strengthen GRAIL’s position in the emerging multi-cancer screening market over the next several quarters.
Clinical Differentiation
The reported clinical performance provides a durable basis for differentiation in a developing diagnostics category. Low false positives, meaningful predictive values, and earlier-stage detection could support physician confidence, regulatory progress, and adoption if the evidence translates into routine screening use.
Liquidity And Low Leverage
Substantial liquidity and very low leverage give GRAIL financial flexibility while it funds commercialization, clinical work, and regulatory activities. The balance sheet can support continued execution without the immediate constraint of heavy debt service, although cash deployment remains important given ongoing losses.
Bears Say
Persistent Unprofitability And Cash Burn
GRAIL remains far from self-funding despite strong revenue growth. Negative gross profit, large operating losses, and substantial cash burn require continued use of cash reserves or external funding, limiting financial resilience and making future profitability dependent on major scale and margin improvement.
NHS-Galleri Endpoint Miss
Failure to meet the study’s primary endpoint weakens the clinical validation supporting broad screening adoption, even though secondary results were positive. This may make regulators, payers, and healthcare partners more cautious and could lengthen the evidence-building process required for durable reimbursement.
Pricing And ASP Pressure
Lower average selling prices can limit the economic benefit of rising test volumes and delay improvement toward sustainable gross margins. Greater reliance on lower-priced channels or employer arrangements may support access and adoption, but it also creates an ongoing constraint on revenue quality and unit economics.
GRAIL Inc News
Hold Rating Reaffirmed as Regulatory Upside Seen Largely Priced In, with Price Target Maintained at $60
Kallum Titchmarsh, an analyst from Morgan Stanley, maintained the Hold rating on GRAIL Inc. The associated price target remains the same with $60.00. Kallum Titchmarsh has given his Hold rating
FDA Advisory Panel Poses Pivotal Binary Event for GRAIL’s Galleri, Keeping Risk‑Reward Balanced and Rating at Hold
Morgan Stanley analyst Kallum Titchmarsh has maintained their neutral stance on GRAL stock, giving a Hold rating on September 8. Kallum Titchmarsh has given his Hold rating due to a
GRAL FAQ
What was GRAIL Inc’s price range in the past 12 months?
What is GRAIL Inc’s market cap?
When is GRAIL Inc’s upcoming earnings report date?
How were GRAIL Inc’s earnings last quarter?
Is GRAIL Inc overvalued?
Does GRAIL Inc pay dividends?
What is GRAIL Inc’s EPS estimate?
How many shares outstanding does GRAIL Inc have?
What happened to GRAIL Inc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of GRAIL Inc?
What is the TipRanks Smart Score and how is it calculated?
GRAIL Inc Stock Smart Score
Company Description
GRAIL Inc
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
- Sector
- General
- Industry
- Medical - Diagnostics & Research
- CEO
- Joshua J. Ofman
- Employees
- 910
- Website
- www.grail.com
- Address
- 1525 O’Brien Drive, Menlo Park, CA, 94025, US
GRAIL Inc (GRAL) Earnings & Revenues
GRAL Earnings Call
Earnings Call SentimentPositive
The call conveyed a generally positive commercial and clinical momentum: strong year-over-year revenue and volume growth, meaningful gross profit improvement, substantial cash including a $110M Samsung strategic investment, and a robust, differentiated clinical evidence base with low false positive rate and high PPV. Key execution items — a completed PMA submission, anticipated FDA advisory committee and sales force expansion — support the company’s pathway to broader access. Offsetting these positives are continued large operating losses and a widened adjusted EBITDA shortfall, the NHS primary endpoint miss, pricing/ASP pressure from channel mix and competitive noise, and timing uncertainty around the FDA advisory committee and U.K. decision-making. Taken together, the highlights (growth, cash runway, unique clinical validation and commercialization readiness) outweigh the lowlights, though execution and regulatory timing risks remain significant.
View all MX:GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 4 | 2 |
| Technical Analysis | 4 | 1 | 2 |
| Moving Averages | 9 | 3 | 0 |
